Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTY720 versus placebo in relapsing-remitting multiple sclerosis (24-month study)
2005-000365-19Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fingolimod in multiple sclerosis (MS) (3 arms), sponsored by Novartis. Primary endpoint: Annualized relapse rate at 24 months. Started Nov 2005; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2005-000365-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000365-19.